A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients with Advanced Solid Tumors

Trial Profile

A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients with Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs IMP 4297 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors IMPACT Therapeutics
  • Most Recent Events

    • 06 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 17 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top